Understanding CFTR dysfunction has paved the way for the development of pharmacologic compounds, including enhancers and correctors, that target specific abnormalities in CFTR function, offering potential therapeutic options for CF patients [60]. This evidence concerns the gene CFTR and cystic fibrosis.